Imaging and Treatment of Gliomas Using Nanoparticles

Information

  • Research Project
  • 6615939
  • ApplicationId
    6615939
  • Core Project Number
    R43CA100976
  • Full Project Number
    1R43CA100976-01
  • Serial Number
    100976
  • FOA Number
    PAR-01-102
  • Sub Project Id
  • Project Start Date
    5/15/2003 - 21 years ago
  • Project End Date
    4/30/2004 - 20 years ago
  • Program Officer Name
    FARAHANI, KEYVAN
  • Budget Start Date
    5/15/2003 - 21 years ago
  • Budget End Date
    4/30/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Imaging and Treatment of Gliomas Using Nanoparticles

DESCRIPTION (provided by applicant): The long term goal of the proposed project is to develop a novel nanoparticle for both molecular imaging and treatment of brain tumors. This Phase I project will contribute to this goal by the synthesis and characterization of a polyacrylamide based-nanoparticle which can be manufactured to contain a contrast agent (Gadolinium). The primary goals of the present proposal are to investigate approaches for enhancement of the efficiency of cellular internalization of the Gadolinium containing nanoparticles into tumor cells so that the efficacy of gadolinium neutron capture therapy (GNCT) can be optimized. We hypothesize that delivery of these nanoparticles with gadolinium contrast agent will provide an opportunity to use MRI to detect the presence and spatial extent of the uptake in tumor tissue. In addition, delivery of gadolinium to tumor tissue intracellularly will provide an opportunity for treatment using GNCT. The purpose of this Phase I application is to provide data revealing that this nanoparticle can be synthesized and internalized in cells, rendering them sensitive to GNCT. We propose to demonstrate that attachment of RGD containing peptides or Avidin to Gd-containing nanoparticles results in enhanced binding and internalization. This proposal will provide proof-of-principle relating to the synthesis, function (imaging) and therapeutic efficacy. It is anticipated that the results obtained from the proposed studies will provide the foundation for future development of these novel nano-structure-based strategies for non-invasive in vivo imaging of tumors and delivery of therapeutic payloads.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    139999
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:139999\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOLECULAR THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    843026449
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48108
  • Organization District
    UNITED STATES